CorNeat Vision Overview
CorNeat Vision is a medical device company developing and marketing novel, permanent and tissue-integrating implants. Our platform material technology, CorNeat EverMatrix™, overcomes the main issue with implants and implantables – the foreign body response they trigger. The EverMatrix™ seamlessly and permanently embeds with live tissue without triggering an inflammatory response. Its durability and flexibility, coupled with its bio-integration capabilities, mark a new era of implants. The EverMatrix™ is set to displace harvested and processed human and animal tissues, including scaffolds and extra cellular matrices, used in a variety of surgical procedures across diversified fields of medicine.
Cumulative Funding Raised Over Time ($)
$4.0MAug 2021
$11.2MDec 2018
$14.6MMay 2020
$16.1MNov 2017
Latest News
growth-positive
/PRNewswire/ -- CorNeat Vision, an innovative ophthalmic medical device company, has announced a groundbreaking clinical achievement: the restoration of...
CorNeat Vision, an ophthalmic medical device company, has achieved a significant milestone in its RESEE clinical trial, reaching 50% enrollment. The trial focuses on the CorNeat KPro, an artificial cornea that has successfully restored perfect vision in a patient blinded by corneal scarring from Shingles. This achievement is notable as the patient was not a candidate for traditional corneal transplantation. The CorNeat KPro integrates with the eye wall, eliminating the need for donor tissue and providing long-term stability. The trial aims for FDA 510(k) clearance and CE Marking, with expansion plans to include US clinical centers by 2026. The project is supported by the European Innovation Council and a U.S. Army Project Award.
Product StageFDA approved/pending approval
growth-positive
FDA Approves Israeli Non-Degradable Synthetic Eye Tissue
The American Food & Drug Administration (FDA) has approved an Israeli-made synthetic tissue substitute for the eye developed by Israeli startup CorNeat Vision. The product, EverPatch, is the world’s first non-degradable synthetic tissue for ophthalmic surgery. It is made of a polymer that stimulates the cells to accept it and incorporate it into the eye tissue. The EverPatch was designed to replace the use of donor tissue, which poses the risk of disease transmission. It will be launched initially in the leading ophthalmic centers in the US in the coming months, and expand nationwide later in the year.
CustomersExpand
growth-positive
CorNeat Vision raises $4 million from Israeli-Chinese GIBF fund
Israel-based medtech startup, CorNeat Vision, has raised $4 million from the Guangzhou Sino-Israel Biotech Investment Fund (GIBF). The funds will be invested in CorNeats Chinese subsidiary in Guangzhou, with the aim to expand the companys activities in the Chinese market. This includes conducting clinical trials, setting up a manufacturing facility, and marketing the companys first two products. CorNeat Vision, founded in 2015, develops a synthetic cornea that operates by inserting artificial optics under the membrane that covers the white of the eyes.
InvestmentExpand
growth-positive
https://www.jpost.com/opinion/hillels-tech-corner-corneat-vision-helping-blind-people-see-again-657891
CorNeat Vision, an Israeli company, has developed a technology that has helped a blind man see again. The company was founded in 2015 and focuses on clinical-stage, biomimetic implant technology. They have invented an artificial cornea and a synthetic non-degradable patch that are currently in clinical trials. They have also developed a glaucoma drainage device and a product for gingival recession that are in advanced animal testing. The company has raised over $12 million from private investors and a Swiss hedge fund. They plan to continue investing in low-medium income countries and offer their solutions there.
InvestmentExpand
growth-positive
Jamal can see again, thanks to new synthetic cornea
CorNeat Vision, a company based in Raanana, has successfully implanted its KPro artificial cornea into a patient, restoring his vision. The patient, Jamal Furani, had lost his vision due to corneal disease and previous donor transplants had failed. The successful surgery took place on January 3rd. CorNeat Visions cofounder, CEO & VP R&D, Almog Aley-Raz, stated that this is the first step in a multinational clinical trial, with the aim of attaining CE Mark, FDA clearance and China NMPA approval. The company plans to initiate a second study later this year.
CustomersPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $18.77M |
| Last funding | $2.5M |
| Stage | B |
| Rounds | 7 |
| Investors | 2 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | www.corneat.com/ |
Locations
4 HaSheizaf Street, Ra'anana, Israel
Photos & Videos
4 item(s)
CorNeat Vision Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Materials & SubstancesImplantsTags (4)
healthcaremedical-devicesvisually-impairedeye-diseasesGeographic Markets
GlobalCorNeat Vision Financials
$18.77M
Total funding
Undisclosed
Capital raised
$2.5M
Last funding
B
Funding stage
7
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$4.0MAug 2021
$11.2MDec 2018
$14.6MMay 2020
$16.1MNov 2017
Private Equity Funding
Undisclosed Round
Aug 2021
$4M
Guangzhou Sino-Israel Biotech Investment Fund (GIBF) (Lead)
B Round
May 2020
$3.4M
Undisclosed Investor(s)
A Round
Dec 2018
$7.2M
Undisclosed Investor(s)
Seed
Nov 2017
$1.45M
Undisclosed Investor(s)
Non-Equity Funding
GrantEvent
May 2022
$2.5M
European Commission (Lead)
GrantEvent
Apr 2018
$200K
China (Shenzhen) Innovation & Entrepreneurship International Competition
GrantEvent
Nov 2017
$15K
Xi'an international startup competition
CorNeat Vision Lifecycle
Cumulative Funding Raised Over Time
$4.0MAug 2021
$11.2MDec 2018
$14.6MMay 2020
$16.1MNov 2017
All Events
Undisclosed Round
Aug 2021
$4M
Guangzhou Sino-Israel Biotech Investment Fund (GIBF) (Lead)
B Round
May 2020
$3.4M
Undisclosed Investor(s)
A Round
Dec 2018
$7.2M
Undisclosed Investor(s)
Seed
Nov 2017
$1.45M
Undisclosed Investor(s)
GrantEvent
May 2022
$2.5M
European Commission (Lead)
GrantEvent
Apr 2018
$200K
China (Shenzhen) Innovation & Entrepreneurship International Competition
GrantEvent
Nov 2017
$15K
Xi'an international startup competition
CorNeat Vision News
13 articles
growth-positive
/PRNewswire/ -- CorNeat Vision, an innovative ophthalmic medical device company, has announced a groundbreaking clinical achievement: the restoration of...
CorNeat Vision, an ophthalmic medical device company, has achieved a significant milestone in its RESEE clinical trial, reaching 50% enrollment. The trial focuses on the CorNeat KPro, an artificial cornea that has successfully restored perfect vision in a patient blinded by corneal scarring from Shingles. This achievement is notable as the patient was not a candidate for traditional corneal transplantation. The CorNeat KPro integrates with the eye wall, eliminating the need for donor tissue and providing long-term stability. The trial aims for FDA 510(k) clearance and CE Marking, with expansion plans to include US clinical centers by 2026. The project is supported by the European Innovation Council and a U.S. Army Project Award.
Product StageFDA approved/pending approval
growth-positive
FDA Approves Israeli Non-Degradable Synthetic Eye Tissue
The American Food & Drug Administration (FDA) has approved an Israeli-made synthetic tissue substitute for the eye developed by Israeli startup CorNeat Vision. The product, EverPatch, is the world’s first non-degradable synthetic tissue for ophthalmic surgery. It is made of a polymer that stimulates the cells to accept it and incorporate it into the eye tissue. The EverPatch was designed to replace the use of donor tissue, which poses the risk of disease transmission. It will be launched initially in the leading ophthalmic centers in the US in the coming months, and expand nationwide later in the year.
CustomersExpand
growth-positive
CorNeat Vision raises $4 million from Israeli-Chinese GIBF fund
Israel-based medtech startup, CorNeat Vision, has raised $4 million from the Guangzhou Sino-Israel Biotech Investment Fund (GIBF). The funds will be invested in CorNeats Chinese subsidiary in Guangzhou, with the aim to expand the companys activities in the Chinese market. This includes conducting clinical trials, setting up a manufacturing facility, and marketing the companys first two products. CorNeat Vision, founded in 2015, develops a synthetic cornea that operates by inserting artificial optics under the membrane that covers the white of the eyes.
InvestmentExpand
growth-positive
https://www.jpost.com/opinion/hillels-tech-corner-corneat-vision-helping-blind-people-see-again-657891
CorNeat Vision, an Israeli company, has developed a technology that has helped a blind man see again. The company was founded in 2015 and focuses on clinical-stage, biomimetic implant technology. They have invented an artificial cornea and a synthetic non-degradable patch that are currently in clinical trials. They have also developed a glaucoma drainage device and a product for gingival recession that are in advanced animal testing. The company has raised over $12 million from private investors and a Swiss hedge fund. They plan to continue investing in low-medium income countries and offer their solutions there.
InvestmentExpand
growth-positive
Jamal can see again, thanks to new synthetic cornea
CorNeat Vision, a company based in Raanana, has successfully implanted its KPro artificial cornea into a patient, restoring his vision. The patient, Jamal Furani, had lost his vision due to corneal disease and previous donor transplants had failed. The successful surgery took place on January 3rd. CorNeat Visions cofounder, CEO & VP R&D, Almog Aley-Raz, stated that this is the first step in a multinational clinical trial, with the aim of attaining CE Mark, FDA clearance and China NMPA approval. The company plans to initiate a second study later this year.
CustomersPartners
https://www.israelhayom.com/2021/01/12/blind-man-sees-again-thanks-to-israeli-startups-artificial-cornea/
growth-positive
CorNeat Vision's First Patient Regains Sight Following Artificial Cornea Implantation at Rabin Medical Center, Ending a Decade of Blindness
CorNeat Vision, an Israel-based biomimetic implant technology company, has successfully implanted its artificial cornea, CorNeat KPro, in a human for the first time. The surgery was performed on a 78-year-old male at Rabin Medical Center, Israel. The CorNeat KPro, which integrates with the eye wall without relying on donor tissue, immediately enabled the patient to read text and recognize family members after the bandages were removed. The company is planning a multi-national clinical trial to attain CE Mark, FDA Clearance and China NMPA approval.
CustomersExpand
growth-positive
First in-human trial of synthetic cornea starts in Israel
CorNeat Visions first-in-human implantation of the CorNeat KPro synthetic cornea has been approved for 10 corneally blind patients at Beilinson Hospital in Petah Tikva. The implant is designed to replace deformed, scarred or opacified corneas and is expected to fully rehabilitate the vision of corneally blind patients immediately following implantation. The clinical trial at Beilinson will be led by Dr. Irit Bahar, chief of ophthalmology. Additional trial sites are planned to open later this year in eight hospitals in Canada, the United States, France, China and the Netherlands.
CustomersExpand
growth-positive
CorNeat Vision's Synthetic Cornea Approved for First-in-Human Implantation
CorNeat Visions synthetic cornea, CorNeat KPro, has received approval to begin a clinical trial at Beilinson Hospital in Israel. The trial will include 10 corneally blind patients who are not candidates for, or have failed one or more corneal transplantations. The device is designed to replace deformed, scarred or opacified corneas and is expected to fully rehabilitate the vision of corneally blind patients immediately following implantation. Additional sites are planned to open later this year in eight leading hospitals in Canada, the United States, France, China and the Netherlands.
CustomersExpand
growth-positive
This Biotech Makes Easily Implantable Artificial Cornea Transplants
Israel-based CorNeat Vision is developing an easily-implantable and affordable artificial cornea that could replace donor corneas in people needing transplants. The companys mission is to address the shortage of donor tissue by developing a cornea made from plastic that is easier to supply and implant than donor corneas. The implant is designed to integrate with eye tissue better than existing synthetic corneas. CorNeat raised a seed round of €1.4M ($1.5M) in 2016 and in 2018, it raised another €6.5M ($7.2M). The company is now applying for clearance to enter phase I trials in humans and hopes to get market approval for the synthetic cornea in 2021.
InvestmentExpand
growth-positive
CorNeat Vision Completes Pre-clinical Phase For Synthetic Cornea and Scleral Patch
Israeli ophthalmic medical solution company, CorNeat Vision, has completed the pre-clinical stage of its cornea implant and the first synthetic, non-degradable scleral patch. The companys solutions, which also include a glaucoma drainage device, will be showcased at the 37th Congress of the ESCRS in Paris, France. CorNeats synthetic biology technology enables its ophthalmic implants to integrate with surrounding tissue. The companys pre-clinical trials proved the safety of its technology as it applied to its synthetic cornea, synthetic scleral patch and glaucoma shunt.
CustomersPartners
growth-positive
https://www.jpost.com/Jpost-Tech/Business-and-Innovation/Spotlight-on-Israeli-startups-Corneat-Vision-artificial-cornea-589759
Corneat Vision, an Israeli company, is developing an artificial cornea to help people suffering from corneal blindness regain their eyesight. The company is currently concluding the pre-clinical phase and plans to enter the clinical phase in June 2019. Two clinical studies are planned in Israel, Canada, the US, France, and China. The companys first device, a tissue substitute for ophthalmic surgeries, is expected to hit the market in late 2020, with the artificial cornea following in mid-2021.
Expand
growth-positive
Israeli co CorNeat Vision unveils artificial cornea
Israeli ophthalmic medical devices startup CorNeat Vision has completed the design and development stage of its artificial cornea implant, CorNeat KPro. The company has successfully trialled the implant in rabbits and is now moving towards biocompatibility and safety tests for human implantation by mid-2018. The CorNeat KPro implant uses advanced cell technology to integrate artificial optics within resident ocular tissue. The companys CEO, Almog Aley-Raz, stated that the implant could provide a remedy for the 20-30 million patients worldwide in need of a solution for corneal pathology.
InvestmentExpand
CorNeat Vision Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 20 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
CorNeat Vision Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 99/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515356293 |
| Crunchbase | corneat-vision |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-11-03T00:00:00.000Z |
| Created | 2017-10-09T00:00:00.000Z |
| Claimed | Yes |